Vol 5, No 3 (2009)
Case report
Published online: 2009-05-15

open access

Page views 571
Article views/downloads 1882
Get Citation

Connect on Social Media

Connect on Social Media

Synchronous appearance of gastrointenstinal stromal tumor and myeloma plasmocyticum with c-kit expression - a case report

Ryszard Pogłód, Maria Kraj, Beata Kwaśniak, Renata Maryniak, Ewa Kalinka-Warzocha, Krzysztof Warzocha
Onkol. Prak. Klin 2009;5(3):109-113.

Abstract

We report a case of a 60-year-old man in whom synchronous appearance of gastrointenstinal stromal tumor (GIST) and myeloma plasmocyticum (MP) with c-kit expression on both tumors. The treatment of MP with VAD (vincristine, adriamycin, dexamethasone), followed by a 9-month administration of thalidomide, combined with melphalan and dexamethasone given once a month, resulted in achieving and maintaining partial remission (PR) for 14 months. The therapy of GIST included a total resection of the tumor and, after tumor metastasizing within abdominal cavity, systemic treatment with c-kit kinase inhibitors. Both 2-month imatinib administration and 2.5-month sunitinib therapy were unsuccessful. The patient died 18 months since diagnosis of both tumors due to progression of GIST, in PR of myeloma. A simultaneous occurrence meof both tumors excludes carcinogenic effect of therapy. Expression of c-kit by cells of both malignancies may suggest one oncogenic event, namely c-kit mutation, in pathogenesis of both tumors. It is also worthy to stress different response of MM and GIST to treatment. This case raises also the question of potential cross-effect of targeted and immunomodulatory therapies on synchronous and/or metachronous neoplasms'clinical course.

Article available in PDF format

View PDF (Polish) Download PDF file

References

  1. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006; 130: 1466–1478.
  2. Nilsson B, Bümming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden. Cancer. 2005; 103(4): 821–829.
  3. Yeh CN, Chen TW, Lee HL, et al. Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: preliminary experience from Chang Gung Memorial Hospital. Ann Surg Oncol. 2007; 14(3): 1123–1128.
  4. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003; 21(23): 4342–4349.
  5. Zsebo KM, Williams DA, Geissler EN, et al. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell. 1990; 63(1): 213–224.
  6. Ocqueteau M, Orfao A, García-Sanz R, et al. Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells. Br J Haematol. 1996; 95(3): 489–493.
  7. Kraj M, Pogłód R, Kopeć-Szlezak J, et al. C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies. Leuk Lymphoma. 2004; 45(11): 2281–2289.
  8. Pruneri G, Ponzoni M, Ferreri AJM, et al. The prevalence and clinical implications of c-kit expression in plasma cell myeloma. Histopathology. 2006; 48(5): 529–535.
  9. Dong C, Hemminki K. Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms. Br J Cancer. 2001; 85(7): 997–1005.
  10. Liszka Ł, Zielińska-Pajak E, Pajak J, et al. Coexistence of gastrointestinal stromal tumors with other neoplasms. J Gastroenterol. 2007; 42(8): 641–649.
  11. Wronski M, Ziarkiewicz-Wroblewska B, Gornicka B, et al. Synchronous occurrence of gastrointestinal stromal tumors and other primary gastrointestinal neoplasms. World J Gastroenterol. 2006; 12(33): 5360–5362.
  12. Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc. 1999; 74(6): 543–552.
  13. Melis M, Choi EA, Anders R, et al. Synchronous colorectal adenocarcinoma and gastrointestinal stromal tumor (GIST). Int J Colorectal Dis. 2007; 22(2): 109–114.
  14. Au WY, Wong WM, Khoo US, et al. Challenging and unusual cases: Case 2. Concurrent gastrointestinal stromal tumor and Burkitt's lymphoma. J Clin Oncol. 2003; 21(7): 1417–1418.
  15. Tzilves D, Gatopoulou A, Zervas K, et al. Development of multiple myeloma in a patient with gastrointestinal stromal tumor treated with imatinib mesylate: a case report. World J Gastroenterol. 2007; 13(13): 2011–2013.
  16. Montero JC, López-Pérez R, San Miguel JF, et al. Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity. Haematologica. 2008; 93(6): 851–859.
  17. Pandiella A, Carvajal-Vergara X, Tabera S, et al. Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents. Br J Haematol. 2003; 123(5): 858–868.
  18. Lemoli RM, Fortuna A. C-kit ligand (SCF) in human multiple myeloma cells. Leuk Lymphoma. 1996; 20(5-6): 457–464.
  19. Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008; 26(33): 5352–5359.
  20. Du CY, Shi YQ, Zhou Ye, et al. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST). J Surg Oncol. 2008; 98(3): 175–178.
  21. Dispenzieri A, Gertz M, Lacy MQ, et al. A phase II trial of imatinib in patients with refractory/relapsed myeloma. Leuk Lymphoma. 2006; 47: 339–342.
  22. Dawson MA, Polizzotto MN, Gordon A, et al. Extramedullary relapse of multiple myeloma presenting as hematemesis and melena. Nat Clin Pract Oncol. 2006; 3(4): 223–326.
  23. Eisen T. Thalidomide in solid malignancies. J Clin Oncol. 2002; 20(11): 2607–2609.